ELITE PHARMACEUTICALS INC /NV/
ELTPUS売上高
$149M
百万USD
営業利益
$49M
百万USD
純利益
$45M
百万USD
ROE
45.4%
最新FY
EPS
$0.03
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | - | $1M | $0.00 |
| FY2021 | Q2 | - | $2M | $0.00 |
| FY2021 | Q3 | - | $2M | $0.00 |
| FY2021 | FY | - | $5M | $0.01 |
| FY2022 | Q1 | $7M | $2M | $0.00 |
| FY2022 | Q2 | $9M | $2M | $0.00 |
| FY2022 | Q3 | $9M | $2M | $0.00 |
| FY2022 | FY | $32M | $9M | $0.01 |
| FY2023 | Q1 | $8M | $0M | $0.00 |
| FY2023 | Q2 | $9M | $2M | $0.00 |
| FY2023 | Q3 | $9M | $3M | $0.00 |
| FY2023 | FY | $34M | $4M | $0.00 |
| FY2024 | Q1 | $9M | $1M | $0.00 |
| FY2024 | Q2 | $14M | $15M | $0.01 |
| FY2024 | Q3 | $16M | $1M | $0.00 |
| FY2024 | FY | $57M | $20M | $0.02 |
| FY2025 | Q1 | $19M | $1M | $0.00 |
| FY2025 | Q2 | $19M | $-11M | $-0.01 |
| FY2025 | Q3 | $14M | $-11M | $-0.01 |
| FY2025 | FY | $84M | $-4M | $0.00 |
| FY2026 | Q1 | $40M | $-6M | $-0.01 |
| FY2026 | Q2 | $36M | $14M | $0.01 |
| FY2026 | Q3 | $32M | $19M | $0.01 |
| FY2026 | FY | $149M | $45M | $0.03 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | - | - | - | $32M | $34M | $57M | $84M | $149M |
| 営業利益 | $-8M | $-7M | $-9M | $-9M | $-2M | $2M | $5M | $4M | $11M | $20M | $49M |
| 純利益 | $-1M | $4M | $-4M | $-9M | $-2M | $5M | $9M | $4M | $20M | $-4M | $45M |
| 総資産 | $32M | $34M | $31M | $24M | $25M | $26M | $35M | $41M | $84M | $96M | $138M |
| 純資産 | - | - | - | - | - | $16M | - | - | - | - | - |
| 自己資本 | $-33M | $26M | $5M | $-3M | $11M | $16M | $25M | $29M | $58M | $54M | $99M |
| 営業CF | - | - | $-5M | $-7M | $-2M | $3M | $7M | $3M | $-3M | $7M | $24M |
| EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $0.00 | $0.01 | $0.01 | $0.00 | $0.02 | $0.00 | $0.03 |
| BPS | $-0.05 | $0.03 | $0.01 | $-0.00 | $0.01 | $0.02 | $0.02 | $0.03 | $0.05 | $0.05 | $0.09 |
| ROE | 2.1% | 14.9% | -80.3% | 370.0% | -21.0% | 31.5% | 35.3% | 12.3% | 34.9% | -8.1% | 45.4% |